Wanbury Ltd received CEP approval from EDQM for the launch of its new product, Dextromethorphan API

Wanbury Limited has been awarded a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines (EDQM) for its Dextromethorphan active pharmaceutical ingredient {API), antitussive (cough) medicine.

The global formulation market for Dextromethorphan is valued at USD 2,500 million for FY24, having grown by 7% over the past year. With the CEP certification, Wanbury is wellpositioned to initiate the commercial sales of this product in European markets.

Shares of Wanbury Limited was last trading in BSE at Rs. 232.70 as compared to the previous close of Rs. 240.35. The total number of shares traded during the day was 6168 in over 74 trades.

The stock hit an intraday high of Rs. 244.80 and intraday low of 228.65. The net turnover during the day was Rs. 1437908.00.

Source : Equity Bulls

Keywords

Wanbury INE107F01022 Pharmaceuticals CEP EDQM Dextromethorphan API AntitussiveCoughMedicine